Third Generation Smallpox Vaccine

Trade Agreement: CETA/WTO-AGP/CPTPP/CFTA/FTAs with Peru/Colombia/Panama/Korea/UK
Tendering Procedures: Generally only one firm has been invited to bid
Non-Competitive Procurement Strategy: Exclusive Rights
Comprehensive Land Claim Agreement: No
Vendor Name and Address: 
Bavarian Nordic A/S
Hejreskovvej 10 A
Denmark
3490
Nature of Requirements: 

Purpose of ACAN:

Public Services and Procurement Canada proposes to negotiate a contract with Bavarian Nordic A/S on behalf of the Public Health Agency of Canada (PHAC) for the purchase of Imvamune®.

Definition of Requirement:

Imvamune® is a third generation, live-attenuated and non-replicating smallpox vaccine. It is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. Although smallpox disease is currently considered to be eradicated, PHAC is procuring a stockpile of the vaccine to immunize Canadians against smallpox disease should a risk ever arise where smallpox is intentionally or unintentionally released.

Quantities:

The estimated quantity for the firm delivery is 500,000 single dose vials, with 250,000 single dose vials in optional quantities. 

Term of Contract:

April 1, 2023 to March 31, 2028.

Evaluation Criteria:

1) Prior to contract award, the vaccine must have Health Canada regulatory approval for active immunization against smallpox, monkeypox and related orthopoxvirus infection and disease in adults 18 years of age and older determined to be at high risk for exposure.

2) The vaccine must have the ability to be stored at a temperature of -80°C ± 10°C, and have a shelf life of no less than 9 years from the date of manufacture.

3) The Vendor must supply the initial requirement of 250,000 single dose vials with a delivery date no later than December 31, 2023.

Delivery:

250,000 single dose vials on or before December 31, 2023; and
250,000 single dose vials on or before December 31, 2024.

As and when required for the optional quantities.

Limited Tendering Reason:

In accordance with Government Contract Regulations (GCRs Part 1 - Conditions of Contract Entry - Bids - 6.(d)), Bavarian Nordic A/S is the only known supplier that manufactures a third generation, live-attenuated and non-replicating smallpox vaccine, licensed in Canada.

Delivery Date: Above-mentioned

You are hereby notified that the government intends to negotiate with one firm only as identified above. Should you have any questions concerning this requirement, contact the contracting officer identified above.

An Advance Contract Award Notice (ACAN) allows departments and agencies to post a notice, for no less than fifteen (15) calendar days, indicating to the supplier community that it intends to award a good, service or construction contract to a pre-identified contractor. If no other supplier submits, on or before the closing date, a Statement of Capabilities that meets the requirements set out in the ACAN, the contracting authority may then proceed with the award.  However, should a Statement of Capabilities be found to meet the requirements set out in the ACAN, then the contracting authority will proceed to a full tendering process.

Suppliers who consider themselves fully qualified and available to provide the services/goods described herein, may submit a statement of capabilities in writing to the contact person identified in this Notice on or before the closing date of this Notice. The statement of capabilities must clearly demonstrate how the supplier meets the advertised requirements.

The PWGSC file number, the contracting officer's name and the closing date of the ACAN must appear on the outside of the envelope in block letters or, in the case of a facsimile transmission, on the covering page.

The Crown retains the right to negotiate with suppliers on any procurement.

Documents may be submitted in either official language of Canada.